Summary
VAU therapy (vinblastine, Adriamycin, and UFT) was given postoperatively to 31 patients with stage I, II, or III renal-cell carcinoma, and the incidence of relapse as well as the survival of patients were studied. Administration was started at 7–14 days post-surgery; 5 mg/m2 vinblastine and 30 mg/m2 Adriamycin were given i.v. once every 4 weeks for a total of five courses, and three capsules of UFT (containing 300 mg tegafur) were given p.o. every day for 2–3 years. The postoperative observation period ranged from 2 years and 6 months to 7 years and 1 month (mean, 4 years and 2 months). The 1-year survival of patients was 100%, and the 3- and 5-year survival values were 96%. These results were significantly better (P<0.01) than the respective values (81%, 72%, and 60%) obtained for the historical controls, i.e., the 60 patients with stage I, II, or III renal-cell carcinoma who received no chemotherapy. Side effects such as alopecia, gastrointestinal symptoms, and myelosuppression were encountered, but all symptoms were so mild and transient that discontinuation of the treatment was not necessary. As VAU therapy might be useful as adjuvant chemotherapy for renal-cell carcinoma, it seems to merit further study.
Similar content being viewed by others
References
DeKernion JB (1983) Treatment of advanced renal cell carcinoma —traditional methods and innovative approaches. J Urol 130: 2
Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. In J Cancer Res 69: 763
Hurshesky WJ, Murphy GP (1977) Current status of therapy of advanced renal carcinoma. J Surg Oncol 9: 277
Kozeki K, Akaza H, Umeda T, Isurugi K, Niijima T (1985) Effects of UFT on far advanced renal cell cancer. Jpn Cancer Chemother 12: 2061
Masuda F, Mori Y, Nakada J (1990) Efficacy of UFT treatment of renal cell carcinoma. In: Murphy GP, Khourys (eds) Therapeutic progress in urological cancers. Alan R. Liss, New York, p 707
Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101: 297
Siminovitch JMP, Montie JE, Straffon RA (1983) Prognostic indicators in renal adenocarcinoma. J Urol 130: 20
Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971) Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28: 1165
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Masuda, F., Nakada, J., Kondo, I. et al. Adjuvant chemotherapy with vinblastine, Adriamycin, and UFT for renal-cell carcinoma. Cancer Chemother. Pharmacol. 30, 477–479 (1992). https://doi.org/10.1007/BF00685600
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685600